Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases. 

Novo Nordisk

Western Innovation (WINN) Initiative

Pacific Economic Development Canada

Innovate BC

Stem Cell Network (SCN)

Genome British Columbia

Rhino Ventures

Pallasite Ventures

Pangaea Ventures

Radical Ventures

Tom Williams

Page One Ventures

Aspect Biosystems

2023 was a big year at Aspect! Watch our Year in Review video to see key highlights from the incredible year gone by. 

Looking forward to an exciting 2024 as we continue our mission to develop bioprinted tissue therapeutics to transform the treatment of serious diseases.

#HIRING | Vice President, Process Development & Manufacturing

We are seeking an experienced cell therapy leader with deep expertise in biopharma process development and cGMP manufacturing to join our growing team.

Learn more + apply: https://buff.ly/49tirEU 
#CellTherapy #Biotech #Biomanufacturing

Happy International Day of Women & Girls in Science! 👩‍🔬🔬 

Today, we recognize and celebrate the invaluable contributions of women in STEM globally and right here at Aspect. 

#WomenInScience #WomenInSTEM #February11

Curious what it's like to be a co-op student at Aspect? Watch the video below to hear from past co-ops about their experience with us! 🔬 💻 🧪

Looking for a co-op role for next term? We're #hiring! Kick-start your career with Aspect and contribute to our mission to transform medicine with bioprinted tissue therapeutics.   

See open roles here 👉 https://buff.ly/2z1cfay 
#AspectLife 

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

DNSSEC

Google Maps

Information Technology

Simon Beyer

Senior Vice President, Process Development and Manufacturing

Jack Harvey

VP, Translational Sciences

Rafal P. Witek

Human Resources

Amanda Fox

Finance and Administration

Claire Cahill

Legal

Joel Goertz

Senior Director, Human Resources

Victoria Currie

Diane Gardiner

Sales and Support

Eric Roos

Microfluidics Engineer

Henrik Persson

Jane Lebkowski

Don Haut

Konrad Walus

Andrew Haughian

Salim Teja

Nancy Krieger

Geoff MacKay

Devyn Smith

Tamer Mohamed

Co-founder & CEO

Co-founder & Chief Technology Officer

Sam Wadsworth

Co-founder & Chief Scientific Officer

Ray Smith

Chief Financial Officer

Rafal Witek

Spiro Getsios

Senior VP, Preclinical R&D

Chief Business Development Officer

Senior VP, Process Development & Manufacturing

Companies With Less Than $500M in Revenue (Top 10K)

Companies With More Than $1M in Revenue (Top 10K)

Companies With Fewer Than 100 Employees (Top 10K)

Companies With More Than 50 Employees (Top 10K)

Aspect Biosystems is a biotechnology company developing bioprinted tissue therapeutics to transform how we treat disease. By combining its proprietary microfluidic 3D bioprinting technology, therapeutic cells, and materials science, Aspect is creating a pipeline of allogeneic cell-based tissue therapeutics to replace or repair damaged organ functions. The company is also partnering with leading researchers and industry innovators worldwide to tackle the biggest challenges in regenerative medicine.

Grant - Aspect Biosystems

Convertible Note - Aspect Biosystems

Venture Round - Aspect Biosystems

Series A - Aspect Biosystems

Seed Round - Aspect Biosystems

Vancouver

British Columbia

Canada

North America

Aspect Biosystems Secures $72.75 Million Government Investment to Advance Bioprinted Tissue Therapeutics

Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada and British Columbia to Advance Development of Bioprinted Tissue Therapeutics

Feds, BC invest nearly $73 million into Aspect Biosystems to establish biomanufacturing facility

Aspect Biosystems announces partnership with governments of Canada and British Columbia

Aspect Biosystems plans $200 million expansion

Aspect Biosystems on LinkedIn: Tamer Mohamed, CEO, Aspect Biosystems

A platform that combines bioprinting technology, therapeutic cells, biomaterials, and computational design to create implantable tissues for treating diseases.

Bioprinted pancreatic tissues designed to maintain normal glycemia in type 1 diabetes patients without the need for immune suppression.

Bioprinted liver tissues aimed at restoring lost or damaged liver function for patients with acquired or genetic liver diseases.

A service involving the computational design of tissues to ensure they are biologically functional and suitable for implantation.

Processing of therapeutic cells and biomaterials to create bioprinted tissues.

Production of bioprinted tissue therapeutics for surgical implantation.

Colombia

South America

Japan

Asia

HTML5

Adobe Fonts

Vimeo

F5 NGINX

.NET 4.5

Amazon EC2

Fonts.com

HubSpot Forms

Google Fonts

Bio INX is a competitor of Aspect Biosystems specializing in 3D tissue engineering and bioprinting.

Bio INX

FloatBio is a competitor of Aspect Biosystems in the field of 3D tissue engineering and bioprinting.

FloatBio

3D BIOPRINTERS is a competitor of Aspect Biosystems specializing in 3D bioprinting and tissue engineering.

3D BIOPRINTERS

Pandorum Technologies is a top competitor of Aspect Biosystems, specializing in advanced 3D bioprinting and tissue engineering technologies.

Pandorum Technologies

Next Big Innovation Labs is a top competitor of Aspect Biosystems, focusing on innovative 3D bioprinting and tissue engineering solutions.

Next Big Innovation Labs

Nano Dimension is a primary competitor of Aspect Biosystems, specializing in advanced 3D printing technologies for various applications.

Nano Dimension

3D Systems is a primary competitor of Aspect Biosystems, known for its advanced 3D printing technologies and solutions.

3D Systems

ExOne is a primary competitor of Aspect Biosystems, specializing in industrial 3D printing technologies.

ExOne

RX Networks is a top competitor of Aspect Biosystems, focusing on advanced technologies in the field of biotechnology.

RX Networks

Chrysalix is a top competitor of Aspect Biosystems, known for its investments and advancements in biotechnology and healthcare technologies.

Chrysalix

Vancouver Computer Vision is a competitor of Aspect Biosystems, specializing in computer vision technologies with potential applications in healthcare.

Vancouver Computer Vision

Aspect Biosystems is a biotechnology company that specializes in the development of 3D tissue models using microfluidics. Their technology platform is designed to enable the creation of living human tissues for drug discovery, therapeutic development, and disease modeling. The company's mission is to revolutionize how the pharmaceutical industry develops drugs by providing more predictive and high-throughput in vitro models.

news impact assignment basic	general
public peers	general	May 14, 2024 7:53 AM	4304fa64
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	35699473
crunchbase profile	general	Nov 22, 2024 9:29 AM	539170f9
li profile	general	May 14, 2024 7:53 AM	623ca5a0
translate crunchbase fundingrounds	general	Nov 22, 2024 2:02 PM	e70e1fc8
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ASPECTBIOSYSTEMS

Aspect Biosystems